Table 2.

Oncologic and nerve sparing outcomes in the MRI group versus controls

Outcome	Control group (%)	pelMRI group (%)	pMRI subgroup (%)	P-value for controls vs pelMRI	P-value for controls vs pMRIa
N	204	204	176
Any NSb	91.5	89.7	90.3	0.6	0.7
Bilateral NS	68.7	73.5	75.0	0.3	0.2
Unilateral NS	22.9	16.2	15.3	0.10	0.069
Bilateral optimal NSb	58.2	56.9	57.4	0.8	0.9
Optimal NS on at least one sideb	88.1	84.7	85.1	0.4	0.5
Pathological Gleason score
No cancer	0.5	0.5	0.6	1.0	1.0
5	0	0.5	0.6	1.0	0.5
6	31.4	29.4	28.4	0.8	0.6
7	49.5	51.0	51.1	0.8	0.8
8	7.8	5.4	5.7	0.4	0.4
9	10.8	13.2	13.6	0.5	0.4
10	0	0	0	N/A	N/A
Any ECE on final pathology	34.8	39.2	39.2	0.4	0.4
Focal ECE	12.8	16.2	15.9	0.4	0.4
Nonfocal ECE	22.1	23.0	23.3	0.9	0.8
Pathological LNI	3.3e	6.9	7.4	0.2	0.10
Pathological SVI	7.8	9.8	10.8	0.6	0.4
Capsular incision into cancerc	3.0	1.5	1.7	0.3	0.5
PSM, all-comersd	19.3	13.7	12.5	0.14	0.092
PSM, cT1c only	18.1	11.0	11.0	0.13	0.12
PSM, cT2/3 only	25.0	21.4	16.7	0.8	0.3
PSM, only patients with nonfocal ECE on final pathology	39.5	27.7	24.4	0.3	0.2

Notes:

^aThe 176 patients with pMRI are here compared with the entire control group (of 204 patients); no rematching was undertaken for this subset analysis.

^bThe three patients with unknown nerve sparing status were excluded from these analyses. Where applicable, one patient with unilateral nerve sparing but unknown levels of nerve sparing was excluded from analysis as well.

^cExcludes 10, 5, and 3 patients with unknown capsular incision into cancer status in the control, pelMRI, and pMRI groups, respectively.

^dOne patient with equivocal margins and one patient with an unknown margin, both in the control group, were excluded from these analyses.

^eExcludes 23 patients with unknown lymph node invasion.

Abbreviations: ECE, extracapsular extension; LNI, lymph node invasion; N/A, not applicable; NS, nerve sparing; pelMRI, pelvic MRI; pMRI, prostate MRI; PSM, positive surgical margin; SVI, seminal vesicle invasion.